β‘ Quick Summary
Sibel Health, a patient monitoring company originating from Northwestern University, has successfully completed a $30 million Series C funding round and has received its seventh FDA clearance for its monitoring platform.
π‘ Key Highlights
- π Funding Details: The Series C round was led by the Steele Foundation for Hope, with participation from DrΓ€ger, both of whom are existing investors in Sibel Health.
- βοΈ FDA Clearance: The latest clearance enhances the ANNE One platform, allowing for alarms and alerts along with a robust central monitoring station.
- π Platform Features: The ANNE One platform includes advanced wearable sensors and AI-driven data analytics, enabling wireless monitoring of vital signs for patients aged 12 and older.
π©ββοΈ About the ANNE One Platform
- The platform consists of two wearable components: the Anne Limb, which tracks skin and body temperature, and the Anne Chest, which monitors heart rate, respiratory rate, step count, fall count, and skin temperature.
- It is designed for continuous monitoring, addressing the critical need for real-time patient data, especially in non-ICU settings.
π Future Plans
- Sibel Health plans to utilize the new funding to accelerate the commercial rollout of the ANNE One platform across hospitals in the U.S. and Europe.
- Dr. Steve Xu, co-founder and CEO, emphasized the importance of continuous monitoring, noting that many patient deaths occur outside of monitored environments.
π Market Developments
- In December, Sibel Health entered a long-term partnership with the Capital Region of Denmark to implement advanced continuous monitoring in hospitals.
- The company has also launched its physiological monitoring platform, Discovery, for clinical trial applications and partnered with Medidata for AI-driven clinical trial solutions.
- In 2022, Sibel raised $33 million in a Series B funding round, further solidifying its position in the health tech market.
1 Comment
Weekly Health & AI Digest β March 21, 2025 - Yesil Science
[…] πΉ Sibel Health Raises $30 Million and Achieves Seventh FDA Clearance […]